Screener
UroGen Pharma URGN Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Marketable securities | 28,842 | 9,711 |
| Restricted cash | 1,329 | 1,350 |
| Accounts receivable, net | 88,757 | 33,082 |
| Inventories | 24,589 | 16,464 |
| Prepaid expenses and other current assets | 12,776 | 14,672 |
| Total current assets | 235,426 | 186,024 |
| Non-current assets: | ||
| Property and equipment, net | 597 | 637 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's inventories?
- UroGen Pharma (URGN) reported inventories of $24.59M in Q2 2026.
- How has UroGen Pharma's inventories changed year-over-year?
- UroGen Pharma's inventories increased by 245.0% year-over-year, from $7.13M to $24.59M.
- What is the long-term trend for UroGen Pharma's inventories?
- Over 5 years (2020 to 2025), UroGen Pharma's inventories has grown at a 53.0% compound annual growth rate (CAGR), from $1.96M to $16.46M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about UroGen Pharma's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude